Industry
Featured experience
Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Korro Bio $70 million private placement
The PIPE consists of common stock
TScan Therapeutics $150 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
EyeCare Partners new refinancing transaction
We advised the superpriority, first-lien and second-lien administrative agent and the fronting bank on the transaction
Intra-Cellular Therapies $500 million stock offering
The shares are listed on the Nasdaq Global Select Market
Nurix Therapeutics $175 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
Biodesix $55 million follow-on offering
The common stock is listed on the Nasdaq Global Market
Adagene $100 million at-the-market offering
We advised Adagene on the offering
Stoke Therapeutics $125 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Select Market
AnHeart Therapeutics acquisition by Nuvation Bio
We are advising AnHeart Therapeutics on the acquisition
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO